IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week TwoBusiness Wire • Tuesday
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockBusiness Wire • 03/26/24
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's AgitationBusiness Wire • 03/20/24
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024Business Wire • 03/20/24
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's PipelineBusiness Wire • 03/12/24
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetBusiness Wire • 02/23/24
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer'sBusiness Wire • 01/23/24
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's TrialBusiness Wire • 01/17/24
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer'sBusiness Wire • 12/19/23
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024Business Wire • 12/13/23
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI InitiativesBusiness Wire • 11/21/23
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief TherapyBusiness Wire • 10/19/23
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical TrialsBusiness Wire • 08/14/23
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto RicoBusiness Wire • 08/02/23
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International ConferenceBusiness Wire • 07/18/23
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's ResearchBusiness Wire • 07/07/23